Hartwig, Morten F. S. http://orcid.org/0000-0001-7102-6951
Bulut, Mustafa
Ravn-Eriksen, Jens
Hansen, Lasse B.
Bojesen, Rasmus D.
Klein, Mads Falk
Jakobsen, Henrik L.
Rasmussen, Morten
Rud, Bo
Eriksen, Jens-Ole
Eiholm, Susanne
Fiehn, Anne-Marie K.
Quirke, Phil
Gögenur, Ismail
Funding for this research was provided by:
Zealand Region
Article History
Received: 9 June 2023
Accepted: 6 August 2023
First Online: 28 September 2023
Declarations
:
: Rasmus D. Bojesen has received financial support from pharmacosmos not related to this study. Morten Rasmussen has received financial support from Olympos and Norgine not related to this study. Phil Quirke is related to Yorkshire Cancer Research, has received consultant fees from Roche and Colonode, and has received financial support from Roche, Bayer, and Amgen. Phil Quirke has a patent pending and participates in an advisory board in corporation with Roche, and is part of the leadership in Bowel Cancer UK. Morten F. S. Hartwig, Mustafa Bulut, Jens Ravn-Eriksen, Lasse B. Hansen, Mads F. Klein, Henrik L. Jakobsen, Bo Rud, Jens-Ole Eriksen, Susanne Eiholm, Anne-Marie K. Fiehn, and Ismail Gögenur have no conflicts of interest or financial ties to disclose.
: The study was approved by the Danish regional ethical committee (SJ-795), registered at ClinicalTrials.gov (NCT04606992), and registered at the Danish regional data protection agency (REG-006-2020). Patients were included after written and oral consent. Data were prospectively collected and stored online at easytrial.com.